PARIS, Feb 7 (Reuters) - Ipsen said a late-stage study of its Decapeptyl drug when injected into patients with locally advanced or metastatic prostate cancer was positive. The results matched the ...
The approval covers a six-month sustained-release version of Decapeptyl®, an LHRH agonist. Debiopharm and its European marketing partner, Ipsen, confirmed regulatory approval of its prostate cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results